Lupus erythematosus
☆ Tamin'ny valin'ny Stiftung Warentest 2022 avy any Alemaina, ny fahafaham-pon'ny mpanjifa amin'ny ModelDerm dia ambany kely noho ny fifampidinihana telemedicine karama.
miseho ho erythema somary volomparasy.
ny lolo mipoitra matetika amin'ny tarehy.
References
Ny famantarana sy fanasokajiana ny cutaneous lupus erythematosus (CLE) dia miteraka fanamby amin'ny diagnostika, manavaka azy amin'ny systemic lupus erythematosus miaraka amin'ny fidiran'ny hoditra. Ny fanadihadiana vao haingana dia nanazava ny fototarazo, ny tontolo iainana ary ny immunologique ao ambanin'ny CLE. Ny fampidirana zava-mahadomelina manokana dia nipoitra ho iray amin'ireo antony lehibe indrindra amin'ny CLE. Ny fitsaboana dia ahitana fitsaboana amin'ny lohahevitra sy rafitra, anisan'izany ny biolojika mampanantena (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , miaraka amin'ny fahombiazan'ny fitsapana klinika.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) dia mirakitra olana amin'ny hoditra isan-karazany, ny sasany amin'izy ireo dia mety mifandray amin'ny olana ara-pahasalamana midadasika kokoa. Izy io dia sokajiana ho karazany samihafa, toy ny acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE dia misy discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus dia vondron'ny aretina autoimmune izay mety hisy fiantraikany amin'ny faritra samihafa amin'ny vatana. Ny karazana sasany, toy ny systemic lupus erythematosus (SLE) , dia misy fiantraikany amin'ny taova maro, fa ny hafa kosa, toa an'i cutaneous lupus erythematosus (CLE) , dia misy fiantraikany amin'ny hoditra indrindra. Manasokajy karazana CLE samihafa izahay mifototra amin'ny fifangaroan'ny famantarana klinika, ny fitsirihana ny tavy ary ny fitsirihana ra, saingy misy fiovaovana be eo amin'ny tsirairay. Matetika ny olan'ny hoditra no mipoitra noho ny fiposahan'ny masoandro, ny fifohana sigara, na ny fanafody sasany.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Ny antony mahatonga ny lupus erythematosus dia tsy mazava. Amin'ireo kambana mitovy, raha misy voan'ny iray dia 24% ny mety ho voan'ny iray hafa. Ny hormonina firaisana ara-nofo amin'ny vehivavy, ny tara-masoandro, ny fifohana sigara, ny tsy fahampian'ny vitamin D, ary ny aretina sasany dia heverina fa mampitombo ny risika.
Ny fitsaboana dia mety ahitana NSAIDs, corticosteroids, immunosuppressants, hydroxychloroquine, ary methotrexate. Na dia mahomby aza ny corticosteroids, ny fampiasana maharitra dia miteraka voka-dratsy.